|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0014582,
umls-concept:C0016360,
umls-concept:C0087111,
umls-concept:C0240951,
umls-concept:C1257890,
umls-concept:C1328050,
umls-concept:C1522673,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
9239
|
|
pubmed:dateCreated |
2001-9-7
|
|
pubmed:abstractText |
Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:AnkerGG,
pubmed-author:BengtssonN ONO,
pubmed-author:BergaSS,
pubmed-author:BlomqvistCC,
pubmed-author:EriksteinBB,
pubmed-author:HolteHH,
pubmed-author:Kellokumpu-LehtinenPP,
pubmed-author:LidbrinkEE,
pubmed-author:LindmanHH,
pubmed-author:LjungmanPP,
pubmed-author:MalmströmPP,
pubmed-author:NilssonJJ,
pubmed-author:OttossonSS,
pubmed-author:SöderlundGG,
pubmed-author:SalminenEE,
pubmed-author:WiklundTT,
pubmed-author:WilkinsBB,
pubmed-author:WiseRR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
356
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1384-91
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11052580-Acute Disease,
pubmed-meshheading:11052580-Adult,
pubmed-meshheading:11052580-Algorithms,
pubmed-meshheading:11052580-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11052580-Breast Neoplasms,
pubmed-meshheading:11052580-Carboplatin,
pubmed-meshheading:11052580-Chemotherapy, Adjuvant,
pubmed-meshheading:11052580-Combined Modality Therapy,
pubmed-meshheading:11052580-Cyclophosphamide,
pubmed-meshheading:11052580-Disease-Free Survival,
pubmed-meshheading:11052580-Epirubicin,
pubmed-meshheading:11052580-Female,
pubmed-meshheading:11052580-Fluorouracil,
pubmed-meshheading:11052580-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11052580-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11052580-Humans,
pubmed-meshheading:11052580-Infusions, Intravenous,
pubmed-meshheading:11052580-Leukemia, Myeloid,
pubmed-meshheading:11052580-Lymphatic Metastasis,
pubmed-meshheading:11052580-Mastectomy, Segmental,
pubmed-meshheading:11052580-Middle Aged,
pubmed-meshheading:11052580-Proportional Hazards Models,
pubmed-meshheading:11052580-Sweden,
pubmed-meshheading:11052580-Thiotepa
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
|
|
pubmed:affiliation |
Radiumhemmet, Karolinska Hospital, Stockholm, Sweden. jonas.bergh@cck.ki.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
